Thoughts on Autolus’s Preclinical Pipeline Update; AACR II 2020 Investor Call Summary
On Thursday, June 25, Autolus held an investor call (press release / presentation), highlighting updated preclinical data from their AUTO5 (T cell lymphoma), AUTO6NG (neuroblastoma, osteosarcoma, small cell lung cancer, and melanoma), and AUTO7 (metastatic castration-resistant prostate cancer, mCRPC) programs. Below, Celltelligence provides thoughts on the significance of these data sets, and the potential impact that Autolus’s next-generation CAR-T products could have on treating solid tumors.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.